Britain approves Valneva’s easy-to-store COVID-19 shot | Inquirer News

Britain approves Valneva’s easy-to-store COVID-19 shot

/ 02:48 PM April 14, 2022

Britain approves Valneva’s easy-to-store COVID-19 shot

A biologist at the French-Austrian biotech firm Valneva works on an inactivated whole-virus vaccine against coronavirus disease (COVID-19) in a laboratory in Vienna, Austria, December 16, 2021. REUTERS FILE PHOTO

Britain approved on Thursday Valneva’s (VLS.PA) COVID-19 vaccine, making it the first country to give a nod to the French firm’s coronavirus shot that is easier to store and involves a process widely used in making flu and polio vaccines.

The shot is also the sixth COVID-19 vaccine to be approved in the UK.

FEATURED STORIES

The Medicines and Healthcare products Regulatory Agency, UK’s independent medicines regulator, said Valneva’s COVID-19 vaccine met the required safety, quality and effectiveness standards.

“It (Valneva shot) is also the first, whole-virus inactivated COVID-19 vaccine to gain regulatory approval in the UK,” the regulator said in a statement.

Article continues after this advertisement

In vaccines such as the one developed by Valneva, the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body but can still trigger an immune response to the novel coronavirus.

Article continues after this advertisement

The shot’s storage temperature — of 2°C to 8°C — is similar to that of a domestic refrigerator, making it appropriate for use in countries where storage at very low temperatures is a challenge.

Article continues after this advertisement

Valneva had said last month it expected a positive recommendation from the European Medicines Agency in April for its COVID-19 vaccine candidate.

RELATED STORIES

Article continues after this advertisement

UK’s Bingham expects Omicron vaccine impact to be known in a week

Pfizer, Moderna jabs give biggest booster impact, UK study finds

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

UK secures 90 million doses of potential coronavirus vaccines

S. Korea approves Phase III trial of SK Bioscience’s COVID-19 vaccine

TAGS: Britain, Health, Valneva

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.